Transcranial Photobiomodulation Therapy

1.Improvements in cognitive function, cerebral perfusion, and cerebral connectivity in patients with dementia.

2.Enhancement of executive function, memory and attention in people with dementia.

What's the technical parameter of the COZING-C320 transcranial photobiomodulation therapy?

1.COZING-C320 helmet is a customizable near infrared light helmet that can be used in your clinical practice or at home for healthcare use by you, your friends and family.

2.Power cord for your location is included to fit your region, ensuring your device is ready to use right out of the box.

3.Durable Carrying Case, Easily carry your device with our stylish and durable carrying case. Designed for convenience and protection.

4.COZING-C320 features 320 premium LEDs emitting 1050nm near-infrared light with adjustable frequency (1-20,000 Hz).

1.OBJECTIVE: To investigate the impact of home implementation of intracranial and intranasal photobiomodulation (PBM) therapy in patients with dementia.

2.BACKGROUND: This study sought to replicate and build on a previously published case series report describing five patients with mild to moderate dementia who experienced improved cognitive function after 12 weeks of intracranial and intranasal near infrared (NIR) PBM therapy.

3.MATERIALS AND METHODS: Eight participants (mean age: 79.8 ± 5.8 years) with physician-diagnosed dementia were randomly assigned to receive either 12 weeks of usual care (UC, n = 4) or home PBM therapy ( n = 4). Study partners were treated with NIR PBM at home three times per week using the COZING-C320 device. Participants were assessed using the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-cog) subscale and the Neuropsychiatric Inventory (NPI) at baseline, week 6, and week 12, as well as arterial spin-labeled perfusion magnetic resonance imaging (MRI) and resting-state functional MRI at baseline and week 12.

RESULTS: At baseline, there were no demographic or clinical differences between the UC and PBM groups. However, after 12 weeks, the PBM group had improved ADAS-cog (group × time interaction: F 1,6 = 16.35, p = 0.007) and NPI (group × time interaction: F 1,6 = 7.52, p = 0.03), increased cerebral perfusion (group × time interaction: F 1,6 = 8.46, p < 0.03), and the default mode network within the posterior cingulate cortex and lateral parietal nodes. connections between the posterior cingulate cortex and lateral parietal nodes within the default mode network were enhanced.

4.CONCLUSION: Because PBM was well tolerated and had no adverse side effects, these results support the potential of PBM therapy as a viable home treatment for patients with dementia.

Hot Tags: transcranial photobiomodulation therapy, China transcranial photobiomodulation therapy manufacturers, suppliers, factory, red light therapy device for brain, light therapy for brain, photobiomodulation brain, photo bio modulation therapy, laser photobiomodulation therapy, brain light therapy device